Scholarlink

Background <p>Many studies explored the features of Chronic obstructive pulmonary disease (COPD) with asthma-like features. We aimed to compare the exacerbation and mortality during one-year follow-up among COPD patients with asthma-like features with different inhalation therapies in the Chinese population (compare Without-inhaled corticosteroids(ICS)and With-ICS inhalation therapy, and then ICS + long-acting β-2-agonist(LABA) and ICS + LABA + long-acting muscarinic antagonists (LAMA).</p> Methods <p>This real-world observational study was conducted in the RealDTC cohort (<b>ChiCTR-POC-17010431</b>,<b> Trial Regisrtation Date: 2017.01.14)</b>. COPD patients with asthma-like features in China from July 1, 2017, to June 31 2022 were recruited into the study and followed-up for 12 months. The Without-ICS inhalation therapy cohort included patients with LAMA or LABA + LAMA therapy, the With-ICS inhalation therapy cohort included patients with ICS + LABA or ICS + LABA + LAMA therapy.</p> Results <p>Of the 2735 eligible participants, the With-ICS inhalation therapy cohort was less likely to experience moderate-to-severe exacerbation and severe exacerbation during follow-up than the Without-ICS inhalation therapy cohort after PSM in multivariate analysis, but not death. The ICS + LABA + LAMA group had a lower risk of moderate-to-severe and frequent exacerbations than the ICS + LABA group after PSM. In addition, patients with CAT ≥ 10, or with previous exacerbation history, or with GOLD II and GOLD III + IV grade, receiving ICS + LABA + LAMA had a decreased risk of exacerbation compared to ICS + LABA.</p> Conclusions <p>COPD patients with asthma-like features with With-ICS inhalation therapy based on bronchodilators were less likely to experience future exacerbations than those Without-ICS inhalation therapy, but not death. In addition, ICS + LABA + LAMA therapy decreased the risk of exacerbation compared to ICS + LABA therapy during follow-up, especially in patients with CAT ≥ 10, or with previous exacerbation history, or with GOLD II and GOLD III + IV grade.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of clinical outcome of COPD with asthma-like feature with different inhalation therapies: a real-world study in the prospective RealDTC cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月2日

查看全文
  • Ling Lin,
  • Wei Cheng,
  • Qing Song,
  • Tao Li,
  • Cong Liu,
  • Ping Zhang,
  • Yuqin Zeng,
  • Dingding Deng,
  • Zhiping Yu,
  • Yan Chen,
  • Ping Chen

摘要

Background

Many studies explored the features of Chronic obstructive pulmonary disease (COPD) with asthma-like features. We aimed to compare the exacerbation and mortality during one-year follow-up among COPD patients with asthma-like features with different inhalation therapies in the Chinese population (compare Without-inhaled corticosteroids(ICS)and With-ICS inhalation therapy, and then ICS + long-acting β-2-agonist(LABA) and ICS + LABA + long-acting muscarinic antagonists (LAMA).

Methods

This real-world observational study was conducted in the RealDTC cohort (ChiCTR-POC-17010431, Trial Regisrtation Date: 2017.01.14). COPD patients with asthma-like features in China from July 1, 2017, to June 31 2022 were recruited into the study and followed-up for 12 months. The Without-ICS inhalation therapy cohort included patients with LAMA or LABA + LAMA therapy, the With-ICS inhalation therapy cohort included patients with ICS + LABA or ICS + LABA + LAMA therapy.

Results

Of the 2735 eligible participants, the With-ICS inhalation therapy cohort was less likely to experience moderate-to-severe exacerbation and severe exacerbation during follow-up than the Without-ICS inhalation therapy cohort after PSM in multivariate analysis, but not death. The ICS + LABA + LAMA group had a lower risk of moderate-to-severe and frequent exacerbations than the ICS + LABA group after PSM. In addition, patients with CAT ≥ 10, or with previous exacerbation history, or with GOLD II and GOLD III + IV grade, receiving ICS + LABA + LAMA had a decreased risk of exacerbation compared to ICS + LABA.

Conclusions

COPD patients with asthma-like features with With-ICS inhalation therapy based on bronchodilators were less likely to experience future exacerbations than those Without-ICS inhalation therapy, but not death. In addition, ICS + LABA + LAMA therapy decreased the risk of exacerbation compared to ICS + LABA therapy during follow-up, especially in patients with CAT ≥ 10, or with previous exacerbation history, or with GOLD II and GOLD III + IV grade.